Objective: This study was conducted to assess the susceptibility of human clinical isolates of Actinomyces species to 12 antimicrobial agents.
Introduction
Actinomycosis is a chronic disease characterized by abscess formation, tissue fibrosis and draining sinuses. It is caused by non-spore-forming species of the genus Actinomyces. The Actinomyces species are Gram positive and commonly filamentous organisms that are facultative anaerobes. The Actinomyces species are commensals and normal inhabitants of the oropharynx, gastrointestinal tract and female genital tract. Four clinical forms of actinomycosis, i.e. cervicofacial, thoracic, abdominopelvic and cerebral account for the majority of infections in humans. The face and neck are the most common sites of actinomycosis. [1] [2] [3] [4] [5] Other sites of infection are less common but share similar features, in that an accurate diagnosis is essential for adequate therapy, which may necessitate at least 6 weeks of antimicrobial chemotherapy. A combined medical-surgical approach is frequently required for extensive disease. 1, 2 The clinical significance of the many recently described Actinomyces spp. has yet to be proven but some, including Actinomyces turicensis and Actinomyces europaeus are clearly associated with mixed infections in superficial soft-tissue abscesses. Those Actinomyces spp. that have been tested are susceptible to a wide range of antimicrobial agents. 7 However, interpretation of different studies is hampered by difficulties in the accurate identification of members of the Actinomyces genus and taxonomic changes. Susceptibility data on accurately identified Actinomyces will become increasingly important as our knowledge of the infections caused by the Actinomyces genus improves.
The aim of this study was to analyse the antimicrobial susceptibility of a wide range of Actinomyces spp. isolated from clinical infections and identified by restriction analysis of amplified 16S ribosomal DNA.
Materials and methods

Clinical strains
Clinical isolates were collected from stored collections held at the Microbiology Department, Edinburgh University, Anaerobe Reference Laboratory, Cardiff, Glasgow Dental Hospital and Glasgow Royal Infirmary.
Identification of isolates
There were 87 isolates available for analysis and each isolate was identified by restriction analysis of amplified 16S ribosomal DNA (ARDRA) as described previously. 8 
Susceptibility testing
The MICs for 12 antibiotics consisting of benzyl penicillin G, amoxicillin, ceftriaxone, linezolid, tetracycline, deoxycycline, clindamycin, erythromycin, clarithromycin, ciprofloxacin, meropenem and piperacillin/tazobactam were obtained by Etest methodology. All tests were performed on freshly poured Wilkens-Chalgren agar plates and were incubated anaerobically for 48-72 h. The plates were inoculated with a bacterial suspension in saline of turbidity equivalent to that of McFarland standard 4.
9 Quality assurance was performed using Bacteroides fragilis (ATCC 25285) and Eubacterium lentum ATCC 43055.
Results
Actinomyces species identified
Use of the ARDRA technique resulted in the identification of 25 Actinomyces israelii, 23 Actinomyces gerencseriae, 11 A. turicensis, 10 Actinomyces funkei, eight Actinomyces graevenitzii and 10 A. europaeus.
Antimicrobial susceptibility
The susceptibilities of the 87 Actinomyces spp. tested are shown in Table 1 . All isolates were susceptible to penicillin and amoxicillin (MIC < 1 mg/L). A number of A. europaeus (2), A. funkei (5) and A. turicensis (9) demonstrated reduced susceptibility ( ‡1 mg/L) to piperacillin/tazobactam. For isolates of A. turicensis, two of the 11 isolates and two of the 10 isolates of A. europaeus demonstrated resistance to erythromycin (MIC > 1 mg/L). All isolates were resistant to ciprofloxacin (MIC > 1 mg/L). Of the 87 isolates tested, only three (3%) had an MIC of linezolid >1.0 mg/L. These isolates comprised 1 A. europaeus (MIC 1.5 mg/L) and two isolates of A. turicensis (MIC 4.0 and >256 mg/L).
Discussion
This report provides a useful insight into the antimicrobial susceptibilities of a number of different species of Actinomyces, including A number of early studies have indicated that many patients respond insufficiently or not at all to penicillin G and have led to the suggestion of prolonged high-dose therapy. 10 However, this may reflect the mixed flora found in the infections from which Actinomyces species may be isolated. Furthermore, antimicrobial agents will poorly penetrate the chronically indurated tissue of actinomycotic lesions and the dense co-aggregations of Actinomyces known as 'sulphur' granules, implying the importance of surgical curettage as adjunctive treatment. Current treatment schemes therefore include drugs effective against actinomycetes and potential b-lactamase producers such as Staphylococcus aureus, Gram-negative anaerobes, and, in cases of abdominal actinomycoses, members of the Enterobacteriaceae.
A possible scheme for the antibiotic treatment of cervicofacial actinomycoses may consist of amoxicillin plus clavulanic acid or possibly ampicillin plus sulbactam. The initial dose is 3 · 2 g amoxicillin plus 3 · 0.2 g clavulanic acid per day for 1 week, and 3 · 1 g amoxicillin plus 3 · 0.1 g clavulanic acid per day for another week. Rarely, chronic cervicofacial infections may require up to 4 weeks of treatment. This regimen may suffice for thoracic actinomycoses, but the high dose continued for 3-4 weeks is recommended. In advanced chronic pulmonary cases, an increased dose of ampicillin may be necessary to increase tissue levels and, depending on the concomitant flora, an aminoglycoside may be necessary if resistant Enterobacteriaceae such as Klebsiella spp. or Enterobacter spp. are present. The latter is generally the case in abdominal actinomycosis. The treatment of choice for these infections is a combination of amoxicillin and clavulanic acid with metronidazole (or clindamycin) for strict anaerobes plus tobramycin or gentamicin. Imipenem and piperacillin/tazobactam may be a suitable alternative, but they have rarely been used for actinomycotic infections. Interestingly, a number of isolates of A. turicensis, A. funkei and A. europaeus displayed elevated MICs of piperacillin/tazobactam.
It should be noted that metronidazole should not be used to treat actinomycotic infections without added antimicrobial agents, since metronidazole is not active against the pathogenic actinomycetes. Patients allergic to penicillin may be treated with tetracyclines or cephalosporins instead of aminopenicillins, but the clinical efficacy of these drugs is much less than that of aminopenicillins or the combination of aminopenicillins with b-lactamase inhibitors.
In conclusion, our data suggest that Actinomyces spp. appear susceptible to a wide range of b-lactam agents and these should be regarded as agents of first choice when combined with b-lactamase inhibitors. Since linezolid, a new agent, has been tested against this group of organisms, it is of interest that apart from one strain of A. turicensis all Actinomyces spp. were susceptible (<4 mg/L) to this antibiotic. Ciprofloxacin and tetracycline performed poorly. This is the first study of antimicrobial susceptibilities for a range of clinical isolates of Actinomyces spp. that have been accurately identified. There are a number of species differences in response to the antibiotics tested, suggesting that accurate identification and speciation may have an impact on clinical outcome. Further clinical studies are required to elucidate the potential role of the antibiotics tested in this study. 
